61310-29-0

Usage

Uses

Used in Pharmaceutical Synthesis:
2-(4-Pyridinyl)-4-pyrimidinamine is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the creation of molecules with specific biological activities, making it an essential component in drug development.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 2-(4-Pyridinyl)-4-pyrimidinamine is employed as a research tool to explore its interactions with biological targets. Its potential as an inhibitor of certain biological processes is being investigated, which could lead to the discovery of new therapeutic agents.
Used in Drug Discovery:
2-(4-PYRIDINYL)-4-PYRIMIDINAMINE is also used in drug discovery efforts, where its properties are harnessed to identify and develop new drugs for the treatment of various diseases. Its role in this process is vital, as it can contribute to the creation of novel therapeutics with improved efficacy and safety profiles.
Used in Chemical Research:
2-(4-Pyridinyl)-4-pyrimidinamine is applied in chemical research to study its reactivity, stability, and potential applications in the synthesis of other organic molecules. This research helps to broaden the understanding of its chemical properties and opens up new avenues for its use in various industries.

InChI:InChI=1/C9H8N4/c10-8-3-6-12-9(13-8)7-1-4-11-5-2-7/h1-6H,(H2,10,12,13)

Upstream product

• 6345-27-3 4-amidinopyridine hydrochloride 
• 920-37-6 2-Chloroacrylonitrile 
• 7461-50-9 2-chloropyrimidin-4-amine 
• 1692-15-5 4-pyridylboronic acid 

Downstream Products

• 61310-12-1 1-tert-butyl-3-(2-pyridin-4-yl-pyrimidin-4-yl)-urea 
• 61310-14-3 1-cyclohexyl-3-(2-pyridin-4-yl-pyrimidin-4-yl)-urea 
• 1459140-19-2 1-(3,4-dichlorophenyl)-3-(2-(pyridin-4-yl)pyrimidin-4-yl)urea 

Relevant academic research and scientific papers

Synthesis and SAR studies of 5-(pyridin-4-yl)-1,3,4-thiadiazol-2-amine derivatives as potent inhibitors of Bloom helicase

Human cells utilize a variety of complex DNA repair mechanisms in order to combat constant mutagenic and cytotoxic threats from both exogenous and endogenous sources. The RecQ family of DNA helicases, which includes Bloom helicase (BLM), plays an important function in DNA repair by unwinding complementary strands of duplex DNA as well as atypical DNA structures such as Holliday junctions. Mutations of the BLM gene can result in Bloom syndrome, an autosomal recessive disorder associated with cancer predisposition. BLM-deficient cells exhibit increased sensitivity to DNA damaging agents indicating that a selective BLM inhibitor could be useful in potentiating the anticancer activity of these agents. In this work, we describe the medicinal chemistry optimization of the hit molecule following a quantitative high-throughput screen of >355,000 compounds. These efforts lead to the identification of ML216 and related analogs, which possess potent BLM inhibition and exhibit selectivity over related helicases. Moreover, these compounds demonstrated cellular activity by inducing sister chromatid exchanges, a hallmark of Bloom syndrome.

Preparation of 2-(pyridinyl)-4-pyrimidinamines

The process of reacting a PY-carboxamidine with α-chloroacrylonitrile in the presence of an acid-acceptor to produce 2-PY-4-pyrimidinamines where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents. The products produced by the process are useful as anti-allergic agents per se and, also, are useful as intermediates in the preparation of other anti-allergic agents, namely, dialkyl N-(2-PY-4-pyrimidinyl)-aminomethylenemalonates and analogs, as well as N-(2-PY-4-pyrimidinyl)ureas.

N-(2-(pyridinyl)-4-pyrimidinyl)-aminomethylenemalonates and analogs

Compounds useful as anti-allergic agents are 2-Q-4-[XZC=C(R)NH]-5-R1 -6-R2 -pyrimidines (I), where Q is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents or N-oxide thereof, R is hydrogen or lower-alkyl, R1 is hydrogen, lower-alkyl or cyano, R2 is hydrogen, lower-alkyl, hydroxy or halo, X and Z are the same or different and are each selected from lower-carbalkoxy, lower-alkanoyl, carbamyl and cyano, or STR1 where R3 and R4 are each lower-alkyl, or X is hydrogen, are prepared by reacting 4-amino-2-Q-5-R1 -6-R2 -pyrimidine (II where Q' is amino) with R'O-C-(R)=CXZ (III). Preparations of II are given. Also shown as intermediates and/or anti-allergic agents are 4-(AcNH)-2-Q-5-R1 -6-R2 -pyrimidines (IV) and 4-(R5 R6 N)-2-Q-5-R1 -6-R2 -pyrimidines (V) where Ac is lower-alkanoyl or lower-carbalkoxy, R5 is hydrogen, lower-alkyl or lower-hydroxyalkyl, and R6 is lower-alkyl or lower-hydroxyalkyl.

5,8-Dihydro-5-oxo-2-(4-or 3-pyridinyl)pyrido[2,3-d]pyrimidine-6-carboxylic acids and esters

Antibacterial 5,8-dihydro-8-(lower-alkyl)-5-oxo-2-Q-4-R2 -6-Z-pyrido[2,3-d]pyrimidine (I) where Z is carboxy or lower-carbalkoxy, R2 is hydrogen or lower-alkyl and Q is 4(or 3)-pyridinyl or 4(or 3)-pyridinyl having one or two lower-alkyl substituents is prepared by heating di-(lower-alkyl) N-(2-Q-6-R2 -4-pyrimidinyl)aminomethylenemalonate (III) to produce 5,8-dihydro-5-oxo-2-Q-4-R2 -6-Z-pyrido[2,3-d]pyrimidine (II) which is tautomeric with 5-hydroxy-2-Q-4-R2 -6-Z-pyrido[2,3-d]pyrimidine (IIA) where Q and R2 are the same as in I above and Z is lower-carbalkoxy, reacting II(or IIA) with a lower-alkylating agent to produce I where Z is lower-carbalkoxy and hydrolyzing this ester (I) to produce I where Z is carboxy. Alternatively, the acid (II or IIA where Z is COOH) can be alkylated after first hydrolyzing the ester (II or IIA where Z is lower-carbalkoxy). The preparations of the intermediate III and intermediates used in its preparation are given.